Sandusky, OH, Oct. 28, 2021 — McapMediaWire — PAO Group, Inc. (OTC Pink: PAOG) today announced the company is entertaining a partnership opportunity to accelerate the ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
The COPD treatment market is anticipated to rise from an estimated $9 billion in 2015 to $14.1 billion in 2025.
Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx.
PAOG has engaged Veristat as a CRO to prepare an IND for the FDA.
PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
The British Medical Journal (BMJ) recently released a report on a case study where CBD demonstrated effectiveness in the treatment of lung cancer and COPD.
RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness.
PAOG has received numerous inquiries into its RespRx developments. Now PAOG is considering a partnership opportunity with a larger organization that has the potential to accelerate the ongoing development of RespRx.
PAOG will release more information as the partnership opportunity develops.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.